Angew Chem Int Ed Engl
April 2023
Two four-coordinate organoboron N,C-chelate complexes with different functional terminals on the PEG chains are studied with respect to their photophysical properties within human MCF-7 cells. Their excited-state properties are characterized by time-resolved pump-probe spectroscopy and fluorescence lifetime microscopy. The excited-state relaxation dynamics of the two complexes are similar when studied in DMSO.
View Article and Find Full Text PDFWe explore the photophysical properties of a family of Ru(II) complexes, , designed as photosensitizers (PSs) for photodynamic therapy (PDT). The complexes incorporate a 1-imidazo[4,5-][1,10]-phenanthroline (ip) ligand appended to one or more thiophene rings. One of the complexes studied herein, (known as TLD1433), is currently in phase II human clinical trials for treating bladder cancer by PDT.
View Article and Find Full Text PDFUnlabelled: TLD1433 is the first Ru(II) complex to be tested as a photodynamic therapy agent in a clinical trial. In this contribution we study TLD1433 in the context of structurally-related Ru(II)-imidozo[4,5-f][1,10]phenanthroline (ip) complexes appended with thiophene rings to decipher the unique photophysical properties which are associated with increasing oligothiophene chain length. Substitution of the ip ligand with ter- or quaterthiophene changes the nature of the long-lived triplet state from metal-to-ligand charge-transfer to ππ* character.
View Article and Find Full Text PDFThis contribution describes the excited-state properties of an Osmium-complex when taken up into human cells. The complex 1 [Os(bpy) (IP-4T)](PF ) with bpy=2,2'-bipyridine and IP-4T=2-{5'-[3',4'-diethyl-(2,2'-bithien-5-yl)]-3,4-diethyl-2,2'-bithiophene}imidazo[4,5-f][1,10]phenanthroline) can be discussed as a candidate for photodynamic therapy in the biological red/NIR window. The complex is taken up by MCF7 cells and localizes rather homogeneously within in the cytoplasm.
View Article and Find Full Text PDF